Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02679144 · ClinicalTrials.gov registry record · Phase 2
Neuroblastoma Maintenance Therapy Trial
A Phase 2 study of Neuroblastoma, sponsored by Giselle Sholler.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 441
- Enrollment target
- 20
- Study locations
NCT02679144: Recruiting Phase 2 study of Neuroblastoma, sponsored by Giselle Sholler.
NCT02679144 is a Phase 2 study of Neuroblastoma that is actively recruiting participants, run by Giselle Sholler. The registered enrollment target is 441 participants, above the 234-participant average among 94 other Neuroblastoma trials with a reported enrollment target (88% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02679144, a Phase 2 study of Neuroblastoma, is actively recruiting participants, sponsored by Giselle Sholler.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 441 participants
- Enrollment target
- 20
- Study locations
Study Summary
Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m2 BID (stratum 1B) on each day of study. This study will focus on the use of DFMO in high risk neuroblastoma patients that are in remission as a strategy to prevent recurrence.
Conditions Studied
Interventions
- DRUG Difluoromethylornithine (DFMO)
Study Locations (20)
Florida
- University of Florida - Gainesville
- Arnold Palmer Hospital for Children - Orlando
- All Children's Hospital Johns Hopkins Medicine - St. Petersburg
- St. Joseph's Children's Hospital - Tampa
California
- UCSF Benioff Children's Hospital Oakland- - Oakland
- Rady Children's Hospital - San Diego
Kentucky
- Kentucky Children's Hospital - Lexington
- Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine - Louisville
Massachusetts
- Tufts Medical Center - Boston
- University of Massachusetts Medical School Worcester - Worcester
Alabama
- University of Alabama, Children's of Alabama - Birmingham
Arkansas
- Arkansas Children's Hospital - Little Rock
Colorado
- Rocky Mountain Pediatric Hematology - Denver
Connecticut
- Connecticut Children's Hospital - Hartford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 441 participants |
| Start Date | 2016-02 |
| Est. Completion | 2033-02 |
| Phase | Phase 2 |
What NCT02679144 shows while recruiting
NCT02679144 is an interventional study that assigns participants to a tested intervention. The registered 441 participants enrollment target is mid-sized for trials with a published cap, above the 234-participant average among 94 other Neuroblastoma trials with a reported enrollment target (88% higher).
The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which Difluoromethylornithine (DFMO) is the first listed.
NCT02679144 names 20 study sites across 14 states, led by Florida, California, Kentucky.
Frequently Asked Questions
What is clinical trial NCT02679144 about?
NCT02679144 is a clinical study titled "Neuroblastoma Maintenance Therapy Trial". Difluoromethylornithine (DFMO) will be used in an open label, single agent, multicenter, study for patients with neuroblastoma in remission. In this study subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 750 mg/m2 ± 250 mg/m2 BID (strata 1, 2, 3, and 4) OR 2500 mg/m...
What is the current status of trial NCT02679144?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 441 participants. The study started on 2016-02. Estimated completion is 2033-02.
What conditions does trial NCT02679144 study?
This clinical trial studies the following conditions: Neuroblastoma.
What interventions are being tested in trial NCT02679144?
The interventions under investigation include: Difluoromethylornithine (DFMO) (DRUG).
Who is sponsoring clinical trial NCT02679144?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02679144 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02679144's enrollment target sits among peer trials
441 12th of 94 higher than 83 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
RECRUITING · Phase 2
-
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 2
-
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
RECRUITING · Phase 2
-
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
RECRUITING · Phase 2
-
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
RECRUITING · Phase 2
-
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704766 · 442 participants · NA
Alpha-Defensin and Synovial Proteins to Improve Detection of Pediatric Septic Arthritis
- NCT04657068 · 442 participants · Phase 1
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- NCT05410145 · 442 participants · Phase 1
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
- NCT06659029 · 442 participants
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia